510(k) device
CardioVision
Icardio.Ai · Adjunctive Heart Failure Status Indicator (QUO, Class II) · First FDA decision Nov 21, 2025, newest Nov 21, 2025Heart failure
Last checked: Nov 19, 2026Source: FDA, CMS, ClinicalTrials.gov, PubMed
FDA decisions
1
510(k) pathway
Device trials
0
Naming "CardioVision"
MAUDE reports
0
Brand "CardioVision", since 2015
PubMed studies
13
Mentioning "CardioVision"
AI summary across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, MAUDE and PubMed data on this page, plus web searches for payment facts.
Product review deck
A slide deck reviewing CardioVision
About ten slides on the technology, clinical evidence, regulatory history and commercialization, built with AI from the data on this page and web research, with sources. Download it as PowerPoint to edit or as PDF to share.
- Executive summary and key facts
- Technology
- Clinical evidence and trials
- Regulatory history and safety
- Reimbursement, market and competition
- Risks, outlook and sources
AI-written from public data and may contain mistakes. Check each fact against its source before relying on it. Not investment, legal, reimbursement or medical advice.
FDA decisions
The newest 1 of 1 decisions filed under this name.
- CardioVision510(k)
K251293 · Decided Nov 21, 2025 · 210 days after receipt
Device type: Adjunctive Heart Failure Status Indicator (QUO) · Cardiology
Medicare coverage
National and local coverage documents whose titles match this device or its device type. Payment add-ons (NTAP, pass-through, TCET) and likely codes are covered in the summary above.
- Implantable Pulmonary Artery Pressure Sensors for Heart Failure ManagementNational determinationOn the books20.36Updated Oct 6, 2026
- Cardiac Rehabilitation Programs for Chronic Heart FailureNational determinationOn the books20.10.1Updated Sep 24, 2026
- Cardiac Contractility Modulation (CCM) for Heart Failure (HF)National determinationOn the books20.39Updated Sep 24, 2026
- Nesiritide for Treatment of Heart Failure PatientsNational analysisReview closedCAG-00289NUpdated Sep 18, 2026
- Implantable Pulmonary Artery Pressure Sensors for Heart Failure ManagementNational analysisReview closedCAG-00466NUpdated Sep 18, 2026
- Cardiac Rehabilitation (CR) Programs - Chronic Heart FailureNational analysisReview closedCAG-00437NUpdated Sep 17, 2026
- Cardiac Contractility Modulation (CCM) for Heart FailureNational analysisReview closedCAG-00469NUpdated Sep 17, 2026
- Nesiritide for Treatment of Heart Failure PatientsNational determinationOn the books200.1Updated Oct 2, 2015
Clinical trials
Device studies on ClinicalTrials.gov that name "CardioVision", any status and sponsor, newest update first.
No registered device study names "CardioVision".
Adverse event reports (MAUDE)
Reports received since 2015 naming the brand "CardioVision", and for the whole product code for context.
This brand
0 reports: 0 malfunction, 0 injury, 0 death
Whole product code QUO
0 reports: 0 malfunction, 0 injury, 0 death
Newest reports for this brand
No MAUDE reports name this brand.
Recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
No recall in FDA's data is linked to these FDA numbers.
Published research
The most relevant PubMed records for "CardioVision"[tiab]. The summary above synthesizes these.
- Detachable Aortic Clamp for Minimally Invasive Cardiac Surgery.
Celmeta B, Viva T, Bisogno A, et al. · Surg Technol Int · 2023
- Usability Evaluation of a Mixed Reality Platform in Pediatric Interventional Cardiology by Specialist Physicians: Mixed Methods Study.
Chilanga CC, Jahnen A, Hafskjold L · JMIR Form Res · 2025Research Support, Non-U.S. Gov't
- CardioVision: A fully automated deep learning package for medical image segmentation and reconstruction generating digital twins for patients with aortic stenosis.
Rouhollahi A, Willi JN, Haltmeier S, et al. · Comput Med Imaging Graph · 2023Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't
- Arterial Stiffness Index and Coronary Artery Plaques in Patients with Subclinical Coronary Atherosclerosis.
Kao YT, Wang ST, Shih CM, et al. · Acta Cardiol Sin · 2015
- CardioVision 2020: program acceptance and progress after 4 years.
Kottke TE, Thomas RJ, Lopez-Jimenez F, et al. · Am J Prev Med · 2006Research Support, Non-U.S. Gov't
- Assessment of test repeatability of arterial stiffness index.
Sharma GK, Gudapati S, Waller JL, et al. · Blood Press Monit · 2005Evaluation Study
- Independent Effects of Hypertension and Obesity on Left Ventricular Mass and Geometry: Evidence from the Cardiovision 2030 Study.
Maugeri A, Hruskova J, Jakubik J, et al. · J Clin Med · 2019
- The Human Induced Pluripotent Stem Cell Test as an Alternative Method for Embryotoxicity Testing.
Galanjuk S, Zühr E, Dönmez A, et al. · Int J Mol Sci · 2022
- Preventing heart disease and stroke: messages from the United States.
Kottke TE, Wu LA · Keio J Med · 2001
- [Data base for body surface potential maps of normal populations--normal data base by the Japanese Circulation Society Task Force Committee on Criteria for Body Surface Mapping].
Ikeda K · Nihon Rinsho · 1995English Abstract, Review
- Mechanical properties and biological interaction of aortic clamps: are these all minimally invasive?
Bianchi G, Pucci A, Matteucci M, et al. · Innovations (Phila) · 2013Comparative Study
- The CardioVision 2020 baseline community report card.
Kottke TE, Brekke MJ, Brekke LN, et al. · Mayo Clin Proc · 2000Research Support, Non-U.S. Gov't
Other devices of this type
Also filed under product code QUO.
- EchoGo Heart Failure (2.0)Ultromics Limited · 510(k) 2024
- Vivio® LVEDP SystemAvicena, LLC · 510(k) 2023
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.